share_log

Aditxt | NT 10-Q: Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB

SEC ·  Nov 15 19:15

Summary by Moomoo AI

Aditxt, Inc., a biotech company based in Mountain View, California, has filed a notification of late filing with the United States Securities and Exchange Commission (SEC) for its Form 10-Q, which was due for the period ended September 30, 2024. The company cited time constraints related to the compilation, dissemination, and review of the required information as the reason for the delay, stating that these constraints made timely filing impracticable without undue hardship and expense. Aditxt has committed to filing the quarterly report no later than five days after the original due date. The notification was signed by CEO Amro Albanna on November 15, 2024. Aditxt confirmed that all other periodic reports have been filed as required and anticipates no significant change in results of operations from the corresponding period of the last fiscal year in the upcoming earnings statements.
Aditxt, Inc., a biotech company based in Mountain View, California, has filed a notification of late filing with the United States Securities and Exchange Commission (SEC) for its Form 10-Q, which was due for the period ended September 30, 2024. The company cited time constraints related to the compilation, dissemination, and review of the required information as the reason for the delay, stating that these constraints made timely filing impracticable without undue hardship and expense. Aditxt has committed to filing the quarterly report no later than five days after the original due date. The notification was signed by CEO Amro Albanna on November 15, 2024. Aditxt confirmed that all other periodic reports have been filed as required and anticipates no significant change in results of operations from the corresponding period of the last fiscal year in the upcoming earnings statements.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more